State Street SPDR S&P Pharmaceuticals ETF
XPH
85 hedge funds and large institutions have $129M invested in State Street SPDR S&P Pharmaceuticals ETF in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 16 increasing their positions, 24 reducing their positions, and 13 closing their positions.
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
8% more funds holding
Funds holding: 79 → 85 (+6)
5.77% less ownership
Funds ownership: 39.88% → 34.11% (-5.8%)
25% less capital invested
Capital invested by funds: $172M → $129M (-$42.9M)
33% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$2.17M |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$2.13M |
| 3 |
Jane Street
New York
|
+$1.97M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.87M |
| 5 |
VF
Virtu Financial
New York
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$17.5M |
| 2 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$7.36M |
| 3 |
TSS
Two Sigma Securities
New York
|
-$5.3M |
| 4 |
WBG
Wharton Business Group
Malvern,
Pennsylvania
|
-$5.13M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$4.25M |
XPH Hedge Fund Activity: Q4 2017 in Review
85 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q4 2017, worth a combined $129M — down 25% from $172M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new XPH positions and 13 closed out — a net gain of 6 holders — while 16 added to existing stakes and 24 trimmed.
The largest buyer was Wells Fargo, adding an estimated $2.17M. The largest seller was Goldman Sachs, cutting an estimated $17.5M.
- 85 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q4 2017, up from 79 in Q3 2017.
- Funds reported $129M of State Street SPDR S&P Pharmaceuticals ETF stock for Q4 2017, down 25% quarter-over-quarter.
- 19 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q4 2017 and 13 closed out, a net change of +6 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q4 2017 was Wells Fargo, an estimated $2.17M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q4 2017 was Goldman Sachs, an estimated $17.5M sold.
Based on aggregated 13F filings for Q4 2017.